Bora Pharmaceuticals has seen significant benefits from its U.S. acquisition, with September revenues surpassing NT$2 billion for the first time, reaching a record NT$2.024 billion. This represents a nearly 100% year-on-year growth rate of 99.24%. Cumulative revenue for the first three quarters reached NT$13.499 billion, up 22.79% from the same period last year. Benefiting from growth in its CDMO (Contract Development and Manufacturing Organization) and global sales businesses, market analysts predict that Bora’s annual revenue could reach NT$20 billion this year, potentially setting a new record in Taiwan's biotech industry. Profitability is expected to start from at least three times its stock capital.
Bora has posted record-breaking revenues for six consecutive months. The integration of its U.S. operations in the third quarter contributed to single-quarter revenue of NT$5.615 billion, representing a quarter-on-quarter growth of 11.6%.
According to Bora, its effective acquisition strategy and ongoing integration efforts have been key to its success. Since September, the company has fully consolidated the revenue of its newly acquired sterile injectables and filling plant in Baltimore, U.S. Additionally, Synpac-Kingdom Pharmaceutical’s Taoyuan plant has successfully shipped and launched APP13007, an ophthalmic drug, to the U.S. market. These operations helped boost global CDMO revenue by over 20% compared to August.
In August, Bora’s global market sales remained strong, particularly in the U.S. Additionally, Bora launched Shionogi’s health and wellness brands under its exclusive agency in Taiwan. The first two products, under the “Healthy Vision” and “Healthy Warmth” initiatives, performed well. The launch of the ESFIGHT (DX) vitamin B complex in collaboration with Great Tree Pharmacy, along with increased visibility of Bora’s own Dr. Bora brand in popular retail channels, continues to enhance the company’s nutritional and health product sales momentum.
To support the rapid growth of its dual-engine business group, Bora recently announced the appointment of J.D. Mowery as General Manager of its global CDMO business. Mowery previously served as President and CEO of KBI Biopharma, a subsidiary of JSR Life Sciences, and brings extensive experience from leading roles in innovative companies such as Genentech, Treadwell Therapeutics, Juno Therapeutics, and Celgene. He also served on the executive teams at CDMO leaders Lonza and AGC Biologics and currently sits on the board of AST, a leading company specializing in advanced sterile filling and packaging technologies. This is the first time Bora has appointed a general manager for one of its business groups, marking a new chapter in the company’s global CDMO expansion. Mowery’s leadership is expected to further increase Bora’s visibility in the global CDMO market and drive the next phase of growth for its CDMO business.
Resource (mandarin):美國併購效益發威 保瑞9月營收改寫新高
